Table 5.

Comparative effectiveness and safety profiles of abrocitinib versus dupilumab[42]

Aspect	Abrocitinib	Dupilumab
EASI-75 Response	Higher response rates at week 2 (RR 1.92), week 12 (RR 1.14), and end (RR 1.12)	Lower response rates at week 2, 12, and end
EASI-90 Response	Higher response rates at week 2 (RR 2.04), week 12 (RR 1.60), and end (RR 1.32)	Lower response rates at week 2, 12, and end
IGA Response	Faster response at week 2 (RR 2.57), week 12 (RR 1.39), and end (RR 1.13)	Slower response at week 2, week 12, and end
PP-NRS4 Response	Faster itch relief at week 2 (RR 1.87), week 12 (RR 1.10), end and (RR 1.20)	Slower itch relief at week 2, week 12, end
Adverse Events	Higher incidence of nausea (RR 6.45), acne (RR 5.21), blood CPK increased (RR 2.27); Lower incidence of conjunctivitis (RR 0.19), nasopharyngitis (RR 0.54)	Lower incidence of nausea, acne; blood CPK increased; higher incidence of conjunctivitis, nasopharyngitis